Trial Profile
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Natural killer cell therapy Shenzhen Hank Bioengineering Institute (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 10 Sep 2019 Status changed from recruiting to completed.
- 12 Jan 2017 New trial record